Gruticibart is under clinical development by Aronora and currently in Phase II for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). According to GlobalData, Phase II drugs for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gruticibart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gruticibart overview

Gruticibart (AB-023) is under development for the treatment of end-stage renal disease. The drug candidate is administered through intravenous route. It is a recombinant monoclonal antibody that selectively targets assembly of the blood contact activation complex. It was under development for the treatment of cardiovascular disease, thrombosis and neurological disorders.

Aronora overview

Aronora operates in pharmaceutical and healthcare industry. It is headquartered in United States.

For a complete picture of Gruticibart’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.